Cantor Fitzgerald announced Corbus Pharma (NASDAQ:CRBP), bumping up its stock price target to $17.00 today
- Updated: October 4, 2016
Just yesterday Corbus Pharma (NASDAQ:CRBP) traded 2.18% higher at $7.02. Corbus Pharma’s 50-day moving average is $5.27 and its 200-day moving average is $3.30. The last stock price is up 112.50% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 537,150 shares of CRBP traded hands, down from an average trading volume of 683,298
In a report announced on 10/05/2016 Cantor Fitzgerald raised the target price of Corbus Pharma (NASDAQ:CRBP) to $17.00 stating a possible upside of 1.42%.
Recent Performance Chart
Corbus Pharma has 52 week low of $1.01 and a 52 week high of $7.88 and has a market capitalization of $0.
In addition to Cantor Fitzgerald reporting its stock price target, a total of 1 brokerage has issued a ratings update on the company. The average stock price target is $6.00 with 0 brokerages rating the stock a strong buy, 2 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Corbus Pharma (NASDAQ:CRBP)
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company's segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. Its product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis, systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis. Resunab is in Phase II clinical stage for the treatment of Systemic Lupus Erythematosus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.